Poulsen Sally-Ann, Bornaghi Laurent F
Chemical Biology Group, Eskitis Institute for Cell and Molecular Therapies, Griffith University, Nathan Campus, Brisbane 4111, Australia.
Bioorg Med Chem. 2006 May 15;14(10):3275-84. doi: 10.1016/j.bmc.2005.12.054. Epub 2006 Jan 20.
A fragment-based drug discovery approach to the synthesis and identification of small molecule inhibitors of bovine carbonic anhydrase II (bCA II) is described. The classical bCA II recognition fragment is an aromatic sulfonamide (ArSO2NH2) moiety. This fragment was incorporated into a scaffold building block, which was subsequently derivatized by dynamic combinatorial chemistry utilizing alkene cross metathesis as the reversible reaction. Screening against bCA II was then carried out and the results allowed determination of the relative bCA II binding affinities of the cross metathesis products that contained the ArSO2NH2 fragment. A bCA II competitive binding assay validated these results with a representative number of pure compounds. The results for screening, without prior isolation of the active constituent, were in full agreement with those obtained for equilibrium dissociation constants (K(i)'s) of pure compounds. Some of these compounds exhibited K(i)'s in the low nanomolar range. Heterogeneous catalysis was shown to be very effective in this drug discovery application of dynamic combinatorial chemistry.
本文描述了一种基于片段的药物发现方法,用于合成和鉴定牛碳酸酐酶II(bCA II)的小分子抑制剂。经典的bCA II识别片段是芳基磺酰胺(ArSO2NH2)部分。该片段被并入一个支架构建模块,随后通过利用烯烃交叉复分解作为可逆反应的动态组合化学进行衍生化。然后对bCA II进行筛选,结果确定了含有ArSO2NH2片段的交叉复分解产物的相对bCA II结合亲和力。bCA II竞争性结合试验用代表性数量的纯化合物验证了这些结果。在不预先分离活性成分的情况下进行筛选的结果与纯化合物的平衡解离常数(K(i))所获得的结果完全一致。其中一些化合物的K(i)处于低纳摩尔范围。在动态组合化学的这种药物发现应用中,非均相催化被证明非常有效。